A new study offers hope for brain cancer patients facing memory loss from radiotherapy. By blocking a single immune receptor, ...
While tremendous relief comes from successfully battling cancer, survivors can also experience cognitive impairments caused by the disease and its treatment. Up to 70% of survivors experience trouble ...
The story of Q32 Bio, a company that develops therapeutics for inflammatory and autoimmune diseases, started two decades ago. That's when V. Michael Holers, MD, a University of Colorado School of ...
Complement Therapeutics GmbH (CTx), a biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) ...
ANX007 targets C1q to inhibit the complement cascade, reducing neuroinflammation and protecting photoreceptors in AMD and GA. The ARCHER trial showed significant vision loss reduction, with a 73% risk ...
CTx001 is an investigational AAV-based gene therapy designed to modulate multiple pathways of the complement system Opti-GAIN is a first-in-human trial to evaluate the safety, tolerability, and ...
What happens when the relief of surviving brain cancer is accompanied by struggles to remember and concentrate, negatively ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback